|3.||BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
|4.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
|5.||Neoplasm Metastasis (Metastasis)
|1.||Liagre, Bertrand: 9 articles (07/2015 - 09/2004)|
|2.||Cocco, Lucio: 8 articles (11/2014 - 05/2002)|
|3.||Ben-David, Yaacov: 8 articles (08/2013 - 03/2004)|
|4.||Ruscetti, Sandra: 8 articles (10/2010 - 04/2003)|
|5.||Beneytout, Jean-Louis: 7 articles (01/2014 - 09/2004)|
|6.||Taketani, Shigeru: 7 articles (10/2009 - 01/2002)|
|7.||Manetti, Dina: 6 articles (11/2014 - 02/2005)|
|8.||Teodori, Elisabetta: 6 articles (11/2014 - 02/2005)|
|9.||Dei, Silvia: 6 articles (11/2014 - 02/2005)|
|10.||Faenza, Irene: 6 articles (06/2014 - 05/2002)|
|1.||Cytarabine (Cytosar-U)FDA LinkGeneric
12/01/1990 - "[Complete remission in erythroleukemia: induced with low dose Ara-C, consolidated with high dose Ara-C]."
06/01/1986 - "[Complete remission obtained in a child with relapse of erythroleukemia by low-dose cytosine arabinoside]."
05/01/1995 - "We have assessed the response of a previously characterized multidrug resistant (MDR) human erythroleukemia cell line (K562R) to the nucleoside analog antimetabolite 1-beta-D-arabinofuranosylcytosine (ara-C). "
08/01/1994 - "We have analyzed the role of c-myc expression in ara-C-induced differentiation of K562 human erythroleukemia cells. "
08/01/1994 - "Essential role of c-myc in ara-C-induced differentiation of human erythroleukemia cells."
|2.||Doxorubicin (Adriamycin)FDA LinkGeneric
01/15/2013 - "Of these, compounds 2b, 2c, 3d, 5a-d and 6d, showed excellent efficacy with a α(max) close to 1. Selected compounds (2d, 3a, 3b, 5a-d) were further studied to evaluate their doxorubicin cytotoxicity potentiation (RF) on doxorubicin-resistant erythroleukemia K562 cells and were found able to enhance significantly doxorubicin cytotoxicity on K562/DOX cells. "
12/01/2009 - "In an attempt to identify more factors associated with MDR for an understanding of the mechanism, we first established an adriamycin (ADR)-resistant human erythroleukemia cell line K562/ADR by stepwise selection in vitro using ADR. "
10/01/2007 - "The Pgp expressing cell line was established from a parental K562 (Erythroleukemia) cell line with increasing concentrations of doxorubicin, and named KDI/20. "
05/01/2006 - "The development of resistance of K562 human erythroleukemia cells to doxorubicin, a widely used antitumor antibiotic with the prooxidant action, leads to changes in the free-radical state of cells. "
03/01/2006 - "In murine erythroleukemia (MEL) A20 cells (grown in 20 ng/ml adriamycin), mutation(s) producing 10-fold adriamycin (doxorubicin) resistance emerged via an unknown mechanism. "
|3.||Transferrin Receptors (Transferrin Receptor)IBA
10/15/2006 - "We have previously reported that an anti-human transferrin receptor IgG3-avidin fusion protein (anti-hTfR IgG3-Av) inhibits the proliferation of an erythroleukemia-cell line. "
02/01/1996 - "We have used quantitative fluorescence microscopy and fluorescence photobleaching recovery to examine the role of metabolic energy in the translational movement of transferrin receptors in the plasma membrane of K562 erythroleukemia cells. "
08/01/1994 - "We used quantitative fluorescence microscopy and fluorescence photobleaching recovery techniques to investigate the translational movement, cell surface expression, and endocytosis of transferrin receptors in K562 human erythroleukemia cells. "
09/01/1991 - "Characterization of transferrin receptor released by K562 erythroleukemia cells."
04/01/1988 - "Involvement of the transferrin receptor cycle was noted in erythroblasts from a patient with erythroleukemia (FAB classification M6). "
|4.||Dimethyl Sulfoxide (DMSO)FDA LinkGeneric
08/01/1994 - "In this study we describe the effect on murine erythroleukemia cells, transfected with a temperature-sensitive mutant p53, of exposure to the differentiating agent dimethylsulfoxide (DMSO). "
03/01/2015 - "The adsorption and transport of hydrophobic molecules at the membrane surface of pre- and post-DMSO induced differentiated murine erythroleukemia (MEL) cells were examined by time- and wavelength-resolved second harmonic light scattering. "
12/01/2013 - "Concurrently, this work lend credence to the concept that DMSO triggers transient activation of p38 signaling and irreversible inhibition of PI3K/AKT signaling pathway, hence uncovering an old conundrum regarding the mechanism by which DMSO induces erythroleukemia cell differentiation. "
01/05/2010 - "Significantly, this regulatory pathway of p45/NF-E2 by P-JNK exists only in uninduced murine erythroleukemia (MEL) cells but not in differentiated MEL cells in which JNK is inactivated on DMSO induction. "
02/15/2008 - "RT-PCR analysis revealed that the HOXC13 and PU.1 genes were expressed in murine erythroleukemia (MEL) cells and their levels decreased during DMSO-induced differentiation into erythroid cells. "
|5.||Interferon-alpha (Interferon Alfa)FDA Link
08/01/1989 - "Long-term remission in a patient with erythroleukemia following interferon-alpha treatment."
05/01/1991 - "DBA/2 mice were injected intravenously with 2 x 10(6) 3C18 Friend erythroleukemia cells (FLC), a cell line resistant to interferon alpha/beta (IFN-alpha/beta). "
10/01/1988 - "Antibody to mouse interferon alpha/beta abrogates resistance to the multiplication of Friend erythroleukemia cells in the livers of allogeneic mice."
01/01/1986 - "In one experimental animal model discussed herein, mice were injected with Friend erythroleukemia cells and treated with mouse interferon alpha/beta. "
04/15/1985 - "The effect of murine interferon-alpha/beta on an established Rauscher murine leukemia virus-induced erythroleukemia in BALB/c mice."
05/09/1997 - "We studied protective effects of NO against tert-butylhydroperoxide (t-BuOOH)-induced oxidations in a subline of human erythroleukemia K562 cells with different intracellular hemoglobin (Hb) concentrations. "
08/17/1999 - "We studied nitric oxide-mediated protection against tert-butyl hydroperoxide (t-BuOOH)-induced cytotoxicity in a subline of human erythroleukemia K562 cells (K/VP.5) and in K/VP.5 cells transduced with a retroviral vector containing the human iNOS gene (K/VP. "
08/17/1999 - "Mechanisms of nitric oxide protection against tert-butyl hydroperoxide-induced cytotoxicity in iNOS-transduced human erythroleukemia cells."
05/09/1997 - "Nitric oxide prevents oxidative damage produced by tert-butyl hydroperoxide in erythroleukemia cells via nitrosylation of heme and non-heme iron. "
|7.||trioctyl phosphine oxide (TOPO)IBA
07/01/1995 - "A Friend murine erythroleukemia cell line (F4-6R) carrying both mdrl and topo II mediated anthracycline resistance was used to determine the efficacy of structurally altered anthracyclines against such extended multidrug resistance. "
12/01/2001 - "Because increased topo II alpha expression is associated with enhanced efficacy of topo II-poisoning antitumor drugs such as etoposide, the hypothesis tested in this report was whether NaB pretreatment could sensitize HL-60 myeloid leukemia and K562 erythroleukemia cells to etoposide-triggered DNA damage and cell death. "
|8.||Messenger RNA (mRNA)IBA
09/01/1992 - "Murine erythroleukemia cells showed a moderate increase followed by a marked decrease in the abundance of p19 mRNA during induction of differentiation. "
04/16/1996 - "In this study, evidence is presented that EPO induces the expression of early response genes c-jun, junD and c-fos mRNA, stimulates jun protein synthesis and induces activation of 5 x AP-1/CAT activity in hyman erythroleukemia K562 cells. "
06/15/1990 - "To study possible mechanisms which could determine ligand specificity of the GPIIb-IIIa complex we investigated whether there are multiple forms of GPIIb mRNA by screening an unamplified lambda gt10 human erythroleukemia cell cDNA library. "
09/15/1989 - "In the current study it was found that K-562 erythroleukemia cells express the superheavy (S) mRNA and the 43 Kd S peptide which were recently discovered in activated T-lymphocytes. "
06/25/1988 - "In this study, we have simultaneously measured steady-state c-myc protein and c-myc mRNA levels in differentiating Friend murine erythroleukemia (MEL) cells. "
01/01/1992 - "Many studies have been devoted to hemoglobin synthesis which is induced in erythroleukemia cells. "
06/07/2013 - "Third, FUT8 also inhibited hemoglobin production of human erythroleukemia K562 cells. "
06/07/2013 - "α-1,6-Fucosyltransferase (FUT8) inhibits hemoglobin production during differentiation of murine and K562 human erythroleukemia cells."
08/01/2008 - "Expression of alpha-hemoglobin stabilizing protein and cellular prion protein in a subclone of murine erythroleukemia cell line MEL."
03/01/2004 - "Hemoglobin content is increased in the human erythroleukemia K562 cell line by a 56.2-kD peptide from uremic plasma."
|10.||Proteins (Proteins, Gene)IBA
03/15/2000 - "In comparison to a 2-D gel separation of the same human erythroleukemia cell line lysate, the IEF-NP RP HPLC produced improved resolution of low mass and basic proteins. "
12/02/1994 - "To study possible mechanisms by which the activity of p50csk might be regulated, we searched for p50csk-interacting proteins in human erythroleukemia cells. "
06/15/1989 - "The aim of this study was to delineate the effects of blocking MVA synthesis on the covalent isoprenylation of these proteins in murine erythroleukemia cells. "
10/01/2012 - "The two fusion proteins exhibited bifunctional activities, namely the pro-proliferation effect on human erythroleukemia cells (TF-1) and SA-mediated high-affinity binding to biotinylated cell surfaces (with an anchoring modified rate of about 99%). "
10/01/2012 - "MTT method was used to evaluate the effect of SA/hGM-CSF fusion proteins in inducing the proliferation of human erythroleukemia cells (TF-1). "
|1.||Drug Therapy (Chemotherapy)
04/01/2011 - "We describe the case of a 62-yr-old man who was diagnosed with erythroleukemia with a complex karyotype and achieved complete hematologic and cytogenetic remission after induction chemotherapy. "
07/01/1989 - "She developed erythroleukemia 88 months after the initiation of chemotherapy, while her myeloma was a complete remission. "
05/15/1983 - "It is suggested that erythroleukemia should be treated with intensive chemotherapy soon after the diagnosis is made."
05/15/1983 - "Erythroleukemia (M6 by French-American-British classification) has long been considered to be resistant to chemotherapy. "
11/01/1982 - "Thus, AAAP therapy seems to be an excellent chemotherapy even for an aged patient with erythroleukemia."
10/01/2010 - "The purpose of study was to investigate the feasibility for establishing erythroleukemia model in CB6F1 mice by transplant with haploidentical mouse leukemic cell line FBL-3 and to explore the biological characteristics of FBL-3 cells in CB6F1 mice, CB6F1 and C57BL/6 mice were inoculated intravenously at doses of 1×10(3)-1×10(7) FBL-3 cells respectively. "
10/01/2010 - "[Establishment of an erythroleukemia model in CB6F1 mice by transplant with haploidentical mouse leukemic cell line FBL-3]."
05/01/1993 - "A case of a male patient with erythroleukemia (blood group O) who received a bone marrow transplant from an HLA-identical sibling (blood group AB) is reported. "
01/01/1986 - "Natural immunity to grafts of FLD-3 erythroleukemia cells by irradiated mice."
07/01/1976 - "[Eight month-complete remission in a case of erythroleukemia treated with intensive chemotherapy, isogeneic bone marrow graft and active immunotherapy (author's transl)]."
10/15/1992 - "The specificity, toxicity, and efficacy of alpha-particle-mediated radioimmunotherapy of murine erythroleukemia was assessed by use of tumor-specific monoclonal antibody 103A labeled with 212Bi. "
10/15/1992 - "Mice treated with 212Bi-103A on day 8 of disease showed no histological evidence of erythroleukemia on day 22 and survived significantly longer (median, 118 days) than mice treated with 212Bi-control IgG (78 days) or untreated mice (63 days), indicating successful specific radioimmunotherapy."
04/01/1987 - "Radioimmunotherapy using 90Y-labeled diethylenetriamine pentaacetic acid-antibody conjugates was studied in Rauscher erythroleukemia virus-infected mice. "
01/01/1987 - "The use of monoclonal antibodies in radioimmunoimaging and radioimmunotherapy was investigated in the Rauscher murine erythroleukemia system. "
12/01/1984 - "Radioimmunotherapy with 131I-labeled monoclonal immunoglobulins was studied using the Rauscher murine erythroleukemia. "
11/01/1994 - "In order to evaluate new and innovative treatments, we and others have used murine models of erythroleukemia and solid tumors with metastatic potential to assess the effects in vivo of bio-immunotherapy. "
05/01/1996 - "On the basis of our previous findings that erythroleukemia-bearing mice of different ages responded positively to immunotherapy [indomethacin +/- recombinant interleukin (rIL-2)] in vivo [stimulated natural killer (NK) cells and increased life span], we aimed, in the present study, to determine if changes in these parameters could be correlated to change in erythroleukemia cell numbers. "
11/01/1982 - "We conclude that AAAP therapy would be useful for remission induction of erythroleukemia."
06/01/1984 - "One patient had erythroleukemia, two cases were heralded by preleukemia with chromosomal abnormalities, one involving the chromosomes 5 and 7. PB is effective in PV; however, despite an easy induction of remission, continuous low-dose maintenance is necessary and the risk of subsequent acute leukemia is still significant."